IVIG (Gamunex-C) Treatment Study for POTS Subjects
Status:
Enrolling by invitation
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to evaluate the symptomatic benefits of immunomodulatory
treatment with IVIG for POTS (postural tachycardia syndrome) patients with evidence of
autoimmunity.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University of Texas Southwestern Medical Center
Collaborators:
Dysautonomia International Grifols Biologicals, LLC